Exevir
3 known investors
ExeVir is a clinical-stage biotech developing single domain antibody (VHH) therapies to prevent and treat infectious diseases, with an initial focus on COVID-19 and dengue. Its modular, multi-specific antibody platform targets vulnerable patients including the immunocompromised.
Investors · 3
Frequently asked questions
- What does Exevir do?
- ExeVir is a clinical-stage biotech developing single domain antibody (VHH) therapies to prevent and treat infectious diseases, with an initial focus on COVID-19 and dengue. Its modular, multi-specific antibody platform targets vulnerable patients including the immunocompromised.
- Who are Exevir's investors?
- Exevir's investors include Fund+, V-Bio Ventures, VIVES Partners.